✦ LIBER ✦

Efficacy and safety of concurrent trastuzumab plus weekly paclitaxel–FEC as primary therapy for HER2-positive breast cancer in everyday clinical practice

✍ Scribed by Sonia Pernas, Miguel Gil-Gil, María Ochoa de Olza, Anna Gumà, Fina Climent, Anna Petit, María Jesús Pla, Amparo García-Tejedor, Ana López-Ojeda, Cati Falo, Adela Fernandez-Otega, Carlos Mesia, Francisco Javier Pérez-Martin, Ander Urruticoechea, Josep Ramon Germà

Book ID: 118796663
Publisher: Springer US
Year: 2012
Tongue: English
Weight: 307 KB
Volume: 134
Category: Article
ISSN: 0167-6806
DOI: 10.1007/s10549-012-2149-7

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Cardiac safety analysis of the first sta

Cardiac safety analysis of the first stage of NSABP B-31, a randomized trial comparing the safety and efficacy of doxorubicin and cyclophosphamide (AC) followed by paclitaxel (T) to that of AC followed by paclitaxel plus trastuzumab (TH) in patients (pts) with operable, node-positive (N+), HER-2 overexpressing breast cancer (HER2+BC)

✍ C Geyer; J Bryant; E Romond; E Tan-Chiu; M Ewer; D Keefe; R Shannon; G Yothers; 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 541 KB

Safety and efficacy of the combination o

Safety and efficacy of the combination of trastuzumab with docetaxel for HER2-positive women with advanced breast cancer. A review of the existing clinical trials and results of the expanded access programme in the UK

✍ K.T. Papazisis; T. Habeshaw; D.W. Miles 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 139 KB